标题
Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 30, Issue 28, Pages 3444-3447
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2012-08-28
DOI
10.1200/jco.2012.41.9580
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
- (2011) J. Cortes et al. ANNALS OF ONCOLOGY
- Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)
- (2011) David Cella et al. BREAST CANCER RESEARCH AND TREATMENT
- The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy
- (2011) Shaheenah Dawood et al. CANCER
- Treatment-Related Mortality With Bevacizumab in Cancer Patients
- (2011) Vishal Ranpura et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
- (2010) Rob Riemsma et al. BREAST CANCER RESEARCH AND TREATMENT
- Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials
- (2010) Stuart D. Russell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
- (2010) S. Geiger-Gritsch et al. ONCOLOGIST
- Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
- (2009) Javier Cortes JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
- (2009) Robert Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
- (2008) Kathy S. Albain et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More